- Home
- MNTK vs KROS Comparison
MNTK vs KROS Comparison
Compare MNTK & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- KROS
- Stock Information
- Founded
- MNTK 1980
- KROS 2015
- Country
- MNTK United States
- KROS United States
- Employees
- MNTK N/A
- KROS N/A
- Industry
- MNTK Natural Gas Distribution
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- MNTK Utilities
- KROS Health Care
- Exchange
- MNTK Nasdaq
- KROS Nasdaq
- Market Cap
- MNTK 339.0M
- KROS 558.9M
- IPO Year
- MNTK 2021
- KROS 2020
- Fundamental
- Price
- MNTK $2.10
- KROS $14.28
- Analyst Decision
- MNTK Hold
- KROS Buy
- Analyst Count
- MNTK 3
- KROS 13
- Target Price
- MNTK $3.33
- KROS $20.63
- AVG Volume (30 Days)
- MNTK 206.2K
- KROS 467.7K
- Earning Date
- MNTK 08-07-2025
- KROS 08-06-2025
- Dividend Yield
- MNTK N/A
- KROS N/A
- EPS Growth
- MNTK N/A
- KROS N/A
- EPS
- MNTK 0.05
- KROS 0.11
- Revenue
- MNTK $179,552,000.00
- KROS $214,713,000.00
- Revenue This Year
- MNTK $2.49
- KROS $5,006.76
- Revenue Next Year
- MNTK $26.02
- KROS N/A
- P/E Ratio
- MNTK $40.80
- KROS $131.15
- Revenue Growth
- MNTK N/A
- KROS 91657.70
- 52 Week Low
- MNTK $1.68
- KROS $9.12
- 52 Week High
- MNTK $6.13
- KROS $72.37
- Technical
- Relative Strength Index (RSI)
- MNTK 44.72
- KROS 63.37
- Support Level
- MNTK $2.22
- KROS $13.26
- Resistance Level
- MNTK $2.78
- KROS $14.83
- Average True Range (ATR)
- MNTK 0.16
- KROS 0.40
- MACD
- MNTK -0.04
- KROS 0.13
- Stochastic Oscillator
- MNTK 0.00
- KROS 79.87
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.